Vertex Pharmaceutic (VRTX)

$477.08 +0.77 (0.16%)
Market Cap 120.89B
Revenue (ttm) 12.00B
Net Income (ttm) 3.95B
EPS (ttm) N/A
PE Ratio 28.55
Forward PE 28.19
Profit Margin 32.94%
Debt to Equity Ratio 0.00
Volume 1,192,000
Avg Vol 1,607,306
Day's Range N/A - N/A
Shares Out 253.81M
Stochastic %K 12%
Beta 0.29
Analysts Strong Sell
Price Target $555.30

Company Profile

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for peo...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 341 6100
Address:
50 Northern Avenue, Boston, United States
FibonacciTrader_
FibonacciTrader_ Jul. 15 at 10:41 PM
Stocks to Keep an Eye On This July $REGN - $663 → $788 $VRTX - $480 → $560 $TMO -$534 → $602 $DXCM - $75 → $85 $MRNA - $67 → $84 Sharing framework and levels - no paywall, just structured positioning thinking Next week’s portfolio and watchlist are live! Head back to my profile to get the latest trading strategies and market analysis.
0 · Reply
JFDI
JFDI Jul. 15 at 7:19 PM
$VRTX monthly MacD cross
0 · Reply
kagrawala
kagrawala Jul. 15 at 2:51 PM
$VRTX market obviously does not like the acquisition. Time will tell if it was a good one. This will reverse if pipeline news is good.
0 · Reply
abman54
abman54 Jul. 15 at 2:42 PM
$VRTX we have had 6 red days in a row. Tech is selling off like crazy and we can’t any bullish movement???
0 · Reply
svertical1
svertical1 Jul. 15 at 1:49 PM
$VRTX Pove Approval Q4 per Grok! https://grok.com/share/c2hhcmQtMw_1a95c149-b4e0-4caf-918e-c19fab59a058
0 · Reply
WallStWireAds
WallStWireAds Jul. 14 at 4:18 PM
$NVCT https://seekingalpha.com/pr/20582379-streetwatch-nuvectis-pharma-eyes-9_8-billion-oral-pnh-market-with-late-stage-nxp100-backed-by $TGTX $VRTX $JBIO $CRNX
0 · Reply
abman54
abman54 Jul. 14 at 2:43 PM
$VRTX 6 red days in a row???
0 · Reply
Scarlasfly
Scarlasfly Jul. 14 at 1:43 PM
$VRTX Is it too much to ask for one green day??
0 · Reply
abman54
abman54 Jul. 13 at 7:14 PM
$VRTX can we go green??!
0 · Reply
NolAsrtormZ
NolAsrtormZ Jul. 13 at 3:41 PM
$ANVS ... lololol $VRTX paid 10 Billion for a excess growth hormone drug. Imagine how much Alzheimers and Parkinsons drugs sell for. At least 20 Billion like Maria wants
0 · Reply
Latest News on VRTX
Vertex Pharmaceuticals price target raised to $585 from $545 at UBS

2026-07-13T16:35:19.000Z - 2 days ago

Vertex Pharmaceuticals price target raised to $585 from $545 at UBS

Vertex Pharmaceuticals price target raised to $560 from $542 at Truist

2026-07-13T13:55:19.000Z - 2 days ago

Vertex Pharmaceuticals price target raised to $560 from $542 at Truist

Vertex Pharmaceuticals price target raised to $600 from $598 at BofA

2026-07-13T11:20:36.000Z - 2 days ago

Vertex Pharmaceuticals price target raised to $600 from $598 at BofA

How to Ride the $2.6 Trillion Merger Boom With High-Growth Stocks

Jul 8, 2026, 3:00 AM EDT - 7 days ago

How to Ride the $2.6 Trillion Merger Boom With High-Growth Stocks

CRNX

Crinetics downgraded to Hold from Buy at TD Cowen

2026-07-07T20:16:07.000Z - 8 days ago

Crinetics downgraded to Hold from Buy at TD Cowen

CRNX

Vertex to Announce Second Quarter 2026 Financial Results on August 3rd

Jul 7, 2026, 4:00 PM EDT - 8 days ago

Vertex to Announce Second Quarter 2026 Financial Results on August 3rd

Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal

2026-07-07T14:00:20.000Z - 8 days ago

Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal

ASND BCRX CRNX

Crinetics shares surge after Vertex agrees to $10B cash buyout

Jul 7, 2026, 9:38 AM EDT - 8 days ago

Crinetics shares surge after Vertex agrees to $10B cash buyout

CRNX

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX)

Jul 7, 2026, 9:28 AM EDT - 8 days ago

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX)

CRNX

Vertex adds ‘genuine fifth commercial pillar’ with deal, says H.C. Wainwright

2026-07-07T11:46:02.000Z - 8 days ago

Vertex adds ‘genuine fifth commercial pillar’ with deal, says H.C. Wainwright

CRNX

This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal

Jul 7, 2026, 7:33 AM EDT - 8 days ago

This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal

CRNX

Vertex Pharmaceuticals price target raised to $570 from $543 at RBC Capital

2026-07-07T11:31:08.000Z - 8 days ago

Vertex Pharmaceuticals price target raised to $570 from $543 at RBC Capital

Vertex Pharmaceuticals price target raised to $350 from $330 at Baird

2026-07-07T10:55:58.000Z - 8 days ago

Vertex Pharmaceuticals price target raised to $350 from $330 at Baird

Crinetics price target raised to $85 from $62 at Baird

2026-07-07T10:50:24.000Z - 8 days ago

Crinetics price target raised to $85 from $62 at Baird

CRNX

Crinetics downgraded to Perform from Outperform at Oppenheimer

2026-07-07T09:55:09.000Z - 8 days ago

Crinetics downgraded to Perform from Outperform at Oppenheimer

CRNX

Why Is Crinetics Stock (CRNX) Surging Nearly 100% in Pre-Market Today, 7/7/26? Analysts React

2026-07-07T08:58:13.000Z - 8 days ago

Why Is Crinetics Stock (CRNX) Surging Nearly 100% in Pre-Market Today, 7/7/26? Analysts React

CRNX

M&A News: Vertex Stock (VRTX) Slips After Announcing the $10B Crinetics Acquisition

2026-07-06T21:23:31.000Z - 9 days ago

M&A News: Vertex Stock (VRTX) Slips After Announcing the $10B Crinetics Acquisition

BAC CRNX MS

Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion

Jul 6, 2026, 5:02 PM EDT - 9 days ago

Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion

CRNX

Vertex Pharmaceuticals Transcript: M&A announcement

Jul 6, 2026, 4:30 PM EDT - 9 days ago

Vertex Pharmaceuticals Transcript: M&A announcement

Vertex Pharmaceuticals Press release: M&A announcement

Jul 6, 2026, 4:30 PM EDT - 9 days ago

Vertex Pharmaceuticals Press release: M&A announcement

Vertex Pharmaceuticals Slides: M&A announcement

Jul 6, 2026, 4:30 PM EDT - 9 days ago

Vertex Pharmaceuticals Slides: M&A announcement

Vertex to acquire Crinetics for $85 per share in cash

2026-07-06T20:10:44.000Z - 9 days ago

Vertex to acquire Crinetics for $85 per share in cash

CRNX

Vertex to buy Crinetics in $10 billion deal

Jul 6, 2026, 4:10 PM EDT - 9 days ago

Vertex to buy Crinetics in $10 billion deal

CRNX

Vertex to Acquire Crinetics Pharmaceuticals

Jul 6, 2026, 4:04 PM EDT - 9 days ago

Vertex to Acquire Crinetics Pharmaceuticals

CRNX

Vertex enters LOI with pan-Canadian Pharmaceutical Alliance for ALYFTREK

2026-07-06T14:30:16.000Z - 9 days ago

Vertex enters LOI with pan-Canadian Pharmaceutical Alliance for ALYFTREK

Vertex announces FDA approval for expanded use of Casgevy

2026-07-02T00:00:10.000Z - 14 days ago

Vertex announces FDA approval for expanded use of Casgevy

Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia

Jul 1, 2026, 7:58 PM EDT - 14 days ago

Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia

US FDA approves Vertex's gene therapy for sickle cell disease in children as young as two

Jul 1, 2026, 6:45 PM EDT - 14 days ago

US FDA approves Vertex's gene therapy for sickle cell disease in children as young as two

3 Companies Redefining Healthcare Innovation

Jun 24, 2026, 7:41 AM EDT - 21 days ago

3 Companies Redefining Healthcare Innovation

CMPS CRSP

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Jun 11, 2026, 7:14 AM EDT - 4 weeks ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE JNJ

Vertex Pharmaceuticals presents new data on Casgevy at EHA

2026-06-11T09:22:17.000Z - 4 weeks ago

Vertex Pharmaceuticals presents new data on Casgevy at EHA

Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions

Jun 11, 2026, 2:01 AM EDT - 4 weeks ago

Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions

Vertex Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 10, 2026, 11:20 AM EDT - 5 weeks ago

Vertex Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

Jun 5, 2026, 12:00 PM EDT - 5 weeks ago

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

Jun 3, 2026, 4:00 PM EDT - 6 weeks ago

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

Jun 1, 2026, 8:00 AM EDT - 6 weeks ago

Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

Vertex Pharmaceuticals Transcript: Bernstein 42nd Annual Strategic Decisions Conference

May 29, 2026, 9:00 AM EDT - 6 weeks ago

Vertex Pharmaceuticals Transcript: Bernstein 42nd Annual Strategic Decisions Conference

Vertex Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 2:35 PM EDT - 2 months ago

Vertex Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

Vertex to Participate in Upcoming May Investor Conferences

May 11, 2026, 4:00 PM EDT - 2 months ago

Vertex to Participate in Upcoming May Investor Conferences

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

May 6, 2026, 7:01 AM EDT - 2 months ago

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

Vertex Pharmaceuticals Earnings Call Transcript: Q1 2026

May 4, 2026, 4:30 PM EDT - 2 months ago

Vertex Pharmaceuticals Earnings Call Transcript: Q1 2026

Vertex Pharmaceuticals Earnings release: Q1 2026

May 4, 2026, 4:30 PM EDT - 2 months ago

Vertex Pharmaceuticals Earnings release: Q1 2026

Vertex Pharmaceuticals Slides: Q1 2026

May 4, 2026, 4:30 PM EDT - 2 months ago

Vertex Pharmaceuticals Slides: Q1 2026

Vertex Pharmaceuticals Quarterly report: Q1 2026

May 4, 2026, 4:30 PM EDT - 2 months ago

Vertex Pharmaceuticals Quarterly report: Q1 2026

Vertex tops profit estimates as sales of new cystic fibrosis drug surge

May 4, 2026, 4:04 PM EDT - 2 months ago

Vertex tops profit estimates as sales of new cystic fibrosis drug surge

Vertex Reports First Quarter 2026 Financial Results

May 4, 2026, 4:01 PM EDT - 2 months ago

Vertex Reports First Quarter 2026 Financial Results

Vertex Pharmaceuticals Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Vertex Pharmaceuticals Proxy statement: Proxy filing

Vertex to Announce First Quarter 2026 Financial Results on May 4th

Apr 6, 2026, 4:00 PM EDT - 3 months ago

Vertex to Announce First Quarter 2026 Financial Results on May 4th

Vertex Pharmaceuticals Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Vertex Pharmaceuticals Proxy statement: Proxy filing

Vertex Pharmaceuticals Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Vertex Pharmaceuticals Proxy statement: Proxy filing

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

Apr 1, 2026, 7:30 AM EDT - 3 months ago

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 4 months ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

Vertex Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 11, 2026, 11:30 AM EDT - 4 months ago

Vertex Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results

Mar 10, 2026, 1:22 PM EDT - 4 months ago

This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results

Vertex passes key test In quest to treat kidney diseases

Mar 10, 2026, 10:54 AM EDT - 4 months ago

Vertex passes key test In quest to treat kidney diseases

Vertex Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 10:00 AM EDT - 4 months ago

Vertex Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Vertex's kidney disease drug meets main goal in late-stage trial

Mar 9, 2026, 4:13 PM EDT - 4 months ago

Vertex's kidney disease drug meets main goal in late-stage trial

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

Mar 9, 2026, 4:02 PM EDT - 4 months ago

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

Vertex to Participate in Upcoming March Investor Conferences

Mar 5, 2026, 4:00 PM EST - 4 months ago

Vertex to Participate in Upcoming March Investor Conferences

Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

Mar 5, 2026, 10:00 AM EST - 4 months ago

Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

Vertex Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 9:10 AM EST - 4 months ago

Vertex Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3

Feb 17, 2026, 4:00 PM EST - 5 months ago

Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3

Vertex Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 12, 2026, 4:30 PM EST - 5 months ago

Vertex Pharmaceuticals Earnings Call Transcript: Q4 2025

Vertex Pharmaceuticals Annual report: Q4 2025

Feb 12, 2026, 4:30 PM EST - 5 months ago

Vertex Pharmaceuticals Annual report: Q4 2025

Vertex Pharmaceuticals Earnings release: Q4 2025

Feb 12, 2026, 4:30 PM EST - 5 months ago

Vertex Pharmaceuticals Earnings release: Q4 2025

Vertex Pharmaceuticals Slides: Q4 2025

Feb 12, 2026, 4:30 PM EST - 5 months ago

Vertex Pharmaceuticals Slides: Q4 2025

Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments

Feb 12, 2026, 4:06 PM EST - 5 months ago

Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments

Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 12, 2026, 4:01 PM EST - 5 months ago

Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

Feb 2, 2026, 10:08 PM EST - 5 months ago

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

Final Trades: Vertex Pharma, Kimberly-Clark, S&P Global and Exxon Mobil

Jan 22, 2026, 1:19 PM EST - 6 months ago

Final Trades: Vertex Pharma, Kimberly-Clark, S&P Global and Exxon Mobil

KMB XOM SPGI

Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th

Jan 20, 2026, 4:00 PM EST - 6 months ago

Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th

Vertex Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 5:15 PM EST - 6 months ago

Vertex Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Vertex Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 5:15 PM EST - 6 months ago

Vertex Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Jan 11, 2026, 5:00 PM EST - 6 months ago

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12

Dec 22, 2025, 4:00 PM EST - 7 months ago

Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12

Vertex's gene therapy shows promise in younger children with blood disorders

Dec 6, 2025, 7:04 AM EST - 7 months ago

Vertex's gene therapy shows promise in younger children with blood disorders

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions

Dec 6, 2025, 7:01 AM EST - 7 months ago

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions

Vertex Pharmaceuticals Transcript: Citi Annual Global Healthcare Conference 2025

Dec 3, 2025, 9:00 AM EST - 8 months ago

Vertex Pharmaceuticals Transcript: Citi Annual Global Healthcare Conference 2025

Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3

Nov 19, 2025, 4:00 PM EST - 8 months ago

Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3

Vertex Pharmaceuticals Transcript: UBS Global Healthcare Conference 2025

Nov 11, 2025, 10:15 AM EST - 8 months ago

Vertex Pharmaceuticals Transcript: UBS Global Healthcare Conference 2025

Vertex Pharmaceuticals Transcript: Study Update

Nov 8, 2025, 8:00 PM EST - 8 months ago

Vertex Pharmaceuticals Transcript: Study Update

Vertex Pharmaceuticals Slides: Study Update

Nov 8, 2025, 8:00 PM EST - 8 months ago

Vertex Pharmaceuticals Slides: Study Update

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

Nov 8, 2025, 5:15 PM EST - 8 months ago

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

Committee stocks on the move: Uber and Vertex Pharma

Nov 4, 2025, 1:22 PM EST - 9 months ago

Committee stocks on the move: Uber and Vertex Pharma

UBER

Vertex Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Vertex Pharmaceuticals Earnings Call Transcript: Q3 2025

Vertex Pharmaceuticals Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Vertex Pharmaceuticals Quarterly report: Q3 2025

Vertex Pharmaceuticals Earnings release: Q3 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Vertex Pharmaceuticals Earnings release: Q3 2025

Vertex Pharmaceuticals Slides: Q3 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Vertex Pharmaceuticals Slides: Q3 2025

Vertex beats quarterly estimates on cystic fibrosis demand, new drugs

Nov 3, 2025, 4:20 PM EST - 9 months ago

Vertex beats quarterly estimates on cystic fibrosis demand, new drugs

Vertex Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 4:02 PM EST - 9 months ago

Vertex Reports Third Quarter 2025 Financial Results

Vertex to Participate in the UBS Global Healthcare Conference on November 11

Oct 27, 2025, 4:00 PM EDT - 9 months ago

Vertex to Participate in the UBS Global Healthcare Conference on November 11

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

Oct 23, 2025, 9:00 AM EDT - 9 months ago

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week

Oct 17, 2025, 9:04 AM EDT - 9 months ago

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week

Vertex to Announce Third Quarter 2025 Financial Results on November 3rd

Oct 6, 2025, 4:00 PM EDT - 10 months ago

Vertex to Announce Third Quarter 2025 Financial Results on November 3rd

Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR

Oct 2, 2025, 1:31 PM EDT - 10 months ago

Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR

IJR NOW

FibonacciTrader_
FibonacciTrader_ Jul. 15 at 10:41 PM
Stocks to Keep an Eye On This July $REGN - $663 → $788 $VRTX - $480 → $560 $TMO -$534 → $602 $DXCM - $75 → $85 $MRNA - $67 → $84 Sharing framework and levels - no paywall, just structured positioning thinking Next week’s portfolio and watchlist are live! Head back to my profile to get the latest trading strategies and market analysis.
0 · Reply
JFDI
JFDI Jul. 15 at 7:19 PM
$VRTX monthly MacD cross
0 · Reply
kagrawala
kagrawala Jul. 15 at 2:51 PM
$VRTX market obviously does not like the acquisition. Time will tell if it was a good one. This will reverse if pipeline news is good.
0 · Reply
abman54
abman54 Jul. 15 at 2:42 PM
$VRTX we have had 6 red days in a row. Tech is selling off like crazy and we can’t any bullish movement???
0 · Reply
svertical1
svertical1 Jul. 15 at 1:49 PM
$VRTX Pove Approval Q4 per Grok! https://grok.com/share/c2hhcmQtMw_1a95c149-b4e0-4caf-918e-c19fab59a058
0 · Reply
WallStWireAds
WallStWireAds Jul. 14 at 4:18 PM
$NVCT https://seekingalpha.com/pr/20582379-streetwatch-nuvectis-pharma-eyes-9_8-billion-oral-pnh-market-with-late-stage-nxp100-backed-by $TGTX $VRTX $JBIO $CRNX
0 · Reply
abman54
abman54 Jul. 14 at 2:43 PM
$VRTX 6 red days in a row???
0 · Reply
Scarlasfly
Scarlasfly Jul. 14 at 1:43 PM
$VRTX Is it too much to ask for one green day??
0 · Reply
abman54
abman54 Jul. 13 at 7:14 PM
$VRTX can we go green??!
0 · Reply
NolAsrtormZ
NolAsrtormZ Jul. 13 at 3:41 PM
$ANVS ... lololol $VRTX paid 10 Billion for a excess growth hormone drug. Imagine how much Alzheimers and Parkinsons drugs sell for. At least 20 Billion like Maria wants
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Jul. 12 at 8:38 AM
📢 $VRTX Bullish Forecast 💊 Vertex Pharmaceuticals is unfolding a strong Elliott Wave sequence. The current structure favors continued upside, with Wave projections pointing toward the $556.9–$646.4 zone. Full Breakdown 👉 https://elliottwave-forecast.com/stock-market/vrtx-elliott-wave-forecast-target-at-556-9-646-4/ #ElliottWave #Trading #Stocks
0 · Reply
BioTechHealthX
BioTechHealthX Jul. 12 at 8:27 AM
$VRTX Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) dominates cystic fibrosis treatment and is now making bold moves into CRISPR gene editing. Discover why many investors believe this biotech stock could lead the next medical revolution. https://biotechhealthx.com/biotech-news/is-vertex-pharma-vrtx-a-smart-stock-to-buy-as-it-expands-beyond-cystic-fibrosis/
0 · Reply
nick_m
nick_m Jul. 11 at 7:01 AM
$NRXP for those who are wondering about the paths and the rise of $NRXP just remember $VRTX at it’s own start
0 · Reply
akinyo
akinyo Jul. 10 at 7:51 PM
$VRTX back to $450, like clock work..
0 · Reply
abman54
abman54 Jul. 10 at 3:01 PM
$VRTX literally bounce at the close yesterday to see it sell off again today?
0 · Reply
Scarlasfly
Scarlasfly Jul. 10 at 2:01 PM
$VRTX Unreal. So many wild swings.
0 · Reply
kagrawala
kagrawala Jul. 10 at 1:46 PM
$VRTX they are going to send it back down to 450 🙄
0 · Reply
abman54
abman54 Jul. 10 at 1:43 PM
$VRTX literally a non tech stock and selling like a tech stock today..
0 · Reply
BPler
BPler Jul. 10 at 1:38 PM
$CRVO Fun fact: In over 12 months I never saw one fact based bearish argument against the actual drug (Neflamapimod) or it's market potential. I would bet most of retail bears never read any scientific paper or data sets from the trials, and wouldn't understand how a successfull product would fit to companies like $VRTX or $BIIB .
0 · Reply
michie
michie Jul. 9 at 6:56 PM
$VRTX added 2 more shs today total 13 shares
0 · Reply
svertical1
svertical1 Jul. 9 at 5:21 PM
$VRTX
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jul. 9 at 4:02 PM
$VRTX I guess the street and shareholders didn't like the BO on $CRNX
0 · Reply